Zimmer Biomet Holdings, Inc. (ZBH) witnessed a significant price drop of $7.18, leading to a 7.76% decrease, currently trading at $85.41. The trading volume surged to $2.36 million, 110.7% above the average, reflecting heightened market activity.
During the latest quarterly earnings call on Monday, April 27th, ZBH reported an EPS of 71 cents, slightly below the consensus estimate of 1.86. The revenue stood at $2 billion, showcasing a mixed performance.
ZBH's dividend per share year-over-year remained stable at $zero, while the forward dividend yield is at 1.12%. The trailing twelve months dividend per share is $1.2, indicating a consistent dividend distribution.
The company experienced a net change in cash of -$700.8 million, primarily driven by debt repayment of $600 million. Operating cash flow stood at $517.30 million, reflecting operational stability amid financial adjustments.
ZBH generated a revenue of $2.24 billion, with a gross profit of $1.45 billion. The net income amounted to $139.5 million, resulting in an EPS of 71 cents. The effective tax rate showed a negative value of -40.71%.
Key ratios for ZBH include a net profit margin of 6.22%, a return on equity of 1.1, and a price to earnings ratio of 31.78, indicating valuation metrics in the current market environment.
ZBH's total assets sum up to $23 billion, with total debt at $7.52 billion, resulting in a net debt of $6.93 billion, reflecting the company's financial positioning.
This report provides insights into ZBH's current financial status, highlighting key performance indicators and market dynamics.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.